Drug Administration Schedule
"Drug Administration Schedule" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
| Descriptor ID |
D004334
|
| MeSH Number(s) |
E02.319.283
|
| Concept/Terms |
Drug Administration Schedule- Drug Administration Schedule
- Administration Schedule, Drug
- Administration Schedules, Drug
- Drug Administration Schedules
- Schedule, Drug Administration
- Schedules, Drug Administration
|
Below are MeSH descriptors whose meaning is more general than "Drug Administration Schedule".
Below are MeSH descriptors whose meaning is more specific than "Drug Administration Schedule".
This graph shows the total number of publications written about "Drug Administration Schedule" by people in this website by year, and whether "Drug Administration Schedule" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 7 | 7 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 8 | 8 |
| 2009 | 0 | 9 | 9 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 9 | 9 |
| 2012 | 0 | 7 | 7 |
| 2013 | 0 | 5 | 5 |
| 2014 | 0 | 7 | 7 |
| 2015 | 0 | 9 | 9 |
| 2016 | 1 | 16 | 17 |
| 2017 | 2 | 218 | 220 |
| 2018 | 1 | 250 | 251 |
| 2019 | 1 | 81 | 82 |
| 2020 | 0 | 54 | 54 |
| 2021 | 0 | 14 | 14 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Administration Schedule" by people in Profiles.
-
Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study. PLoS One. 2021; 16(9):e0256977.
-
Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. Am Heart J. 2021 12; 242:115-122.
-
Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19. Clin Transl Sci. 2021 11; 14(6):2556-2565.
-
Population pharmacokinetics of favipiravir in patients with COVID-19. CPT Pharmacometrics Syst Pharmacol. 2021 10; 10(10):1161-1170.
-
Adjunctive corticosteroid treatment for organizing pneumonia in COVID-19 patients with persistent respiratory failure. Respir Med. 2021 10; 187:106571.
-
COVID-19 in Cladribine-treated patient with multiple sclerosis. J Neuroimmunol. 2021 10 15; 359:577690.
-
Impact of early corticosteroids on 60-day mortality in critically ill patients with COVID-19: A multicenter cohort study of the OUTCOMEREA network. PLoS One. 2021; 16(8):e0255644.
-
Inhaled Budesonide Reduces the Risk of Emergency Department Evaluation or Hospitalization in Early COVID-19. Am Fam Physician. 2021 08 01; 104(2):207-208.
-
Evaluation of the dose-effect association between the number of doses and duration since the last dose of COVID-19 vaccine, and its efficacy in preventing the disease and reducing disease severity: A single centre, cross-sectional analytical study from India. Diabetes Metab Syndr. 2021 Sep-Oct; 15(5):102238.
-
Vitamin D supplementation prior to or during COVID-19 associated with better 3-month survival in geriatric patients: Extension phase of the GERIA-COVID study. J Steroid Biochem Mol Biol. 2021 10; 213:105958.